Sarepta Therapeutics (SRPT) Non-Current Assets (2010 - 2026)

Sarepta Therapeutics' Non-Current Assets history runs 17 years deep, the most recent figure standing at $869.1 million for Q1 2026.

• On a quarterly basis, Non-Current Assets fell 15.86% year-over-year to $869.1 million in Q1 2026; TTM through Mar 2026 was $3.5 billion, a 2.88% decrease from a year earlier, with the FY2025 full-year figure at $811.8 million, down 8.76% from the prior year.
• Non-Current Assets climbed to $869.1 million in Q1 2026 per SRPT's latest filing, from $811.8 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $1.0 billion in Q1 2025 and bottomed at $525.2 million in Q1 2022.
• The 5-year median for Non-Current Assets is $740.6 million (2024), against an average of $737.3 million.
• Across the five-year window, Non-Current Assets jumped 38.81% in 2024 and decreased 15.86% in 2026, its largest moves.
• Year by year, Non-Current Assets stood at $570.5 million in 2022, then advanced by 20.11% to $685.2 million in 2023, then rose by 29.84% to $889.7 million in 2024, then declined by 8.76% to $811.8 million in 2025, then gained by 7.06% to $869.1 million in 2026.
• Per Business Quant, the three latest SRPT Non-Current Assets figures stand at $869.1 million (Q1 2026), $811.8 million (Q4 2025), and $771.1 million (Q3 2025).